Tradestie Institutional Equity Comparison Engine
MBIO vs NVO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NVO Overall Edge
NVO Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Novo-Nordisk A/S (NVO) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, MBIO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus NVO at 12.5x Forward P/E and 50.8% operating margin (+5.6% YoY). In options structure, MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against NVO sits in CONSOLIDATION (32nd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
NVO
MBIO N/M vs NVO 12.5x Fwd P/E
Growth & Margin Winner
NVO
Op Margin 0.0% vs 50.8% ยท YoY +0.0% vs +5.6%
Momentum & Technical Winner
NVO
1Y -68.4% vs -15.4% ยท 52W Pos 3% vs 22%
Options & Structure Winner
NVO
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (32nd %ile IV)
MBIO
NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-2.46% 1D
Market Cap
$3.2M
1M Return
+3.22%
1Y Return
-68.44%
Forward P/E
N/M
Unified AI Score
42.9 / 100
HOLD
Tech 40.0
Fund 49.0
Flow 50.0
Mom 70.0
NVO
NYSE
Novo-Nordisk A/S
Pharmaceutical Preparations
$41.60
-0.07% 1D
Market Cap
$183.5B
1M Return
+7.13%
1Y Return
-15.38%
Forward P/E
12.5x
Unified AI Score
35.1 / 100
SELL
Tech 37.0
Fund 48.0
Flow 58.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MBIO -68.44%
NVO -15.38%
Spread: +53.85 pp (NVO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
MBIO TTM Op. Margin: 0.0%
NVO TTM Op. Margin: 50.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs NVO. Trailing 12-month operating profitability (MBIO 0.0% vs NVO 50.8%) and valuation multiples (MBIO N/M vs NVO 12.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MBIO | NVO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.2M | $183.5B | Larger Scale | NVO |
| Trailing P/E Ratio Valuation | N/M | 10.5x | Lower Multiple | NVO |
| Forward P/E Ratio Valuation | N/M | 12.5x | Lower Multiple | NVO |
| Revenue Growth (YoY) Growth | +0.0% | +5.6% | Higher Growth | NVO |
| Operating Margin (TTM) Profitability | 0.0% | 50.8% | Higher Margin | NVO |
| Net Profit Margin Profitability | 0.0% | 33.9% | Higher Margin | NVO |
| Return on Equity (ROE) Capital Efficiency | -43.1% | 58.4% | Higher ROE | NVO |
| 52-Week Range Position Momentum | 3% ($0โ$1) | 22% ($35โ$64) | Stronger Trend | NVO |
| Beta / 30D Volatility Risk Regime | 0.68ฮฒ ยท 87% Vol | 0.50ฮฒ ยท 32% Vol | Lower Realized Risk | NVO |
| Unified Institutional Score Composite Signal | 42.9 / 100 (HOLD) | 35.1 / 100 (SELL) | Higher Composite | MBIO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MBIO vs NVO Buy Guide
MBIO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
NVO
CONSOLIDATION
95d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
32nd %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MBIO nor NVO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.